Treace Medical Concepts (NASDAQ:TMCI) Releases Earnings Results, Beats Estimates By $0.02 EPS

Treace Medical Concepts (NASDAQ:TMCI) announced its earnings results on Thursday. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.02, Zacks reports. Treace Medical Concepts had a negative net margin of 23.01% and a negative return on equity of 46.76%. Treace Medical Concepts updated its FY 2025 guidance to EPS.

Treace Medical Concepts Trading Down 0.3%

NASDAQ:TMCI traded down $0.02 during trading hours on Thursday, hitting $6.23. The stock had a trading volume of 569,049 shares, compared to its average volume of 228,582. Treace Medical Concepts has a one year low of $5.16 and a one year high of $10.79. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.51 and a current ratio of 3.52. The company has a market cap of $393.55 million, a price-to-earnings ratio of -7.89 and a beta of 0.68. The business’s 50 day moving average is $6.71 and its 200-day moving average is $6.43.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on TMCI shares. Truist Financial dropped their price target on shares of Treace Medical Concepts from $8.00 to $7.00 and set a “hold” rating for the company in a research note on Wednesday, October 15th. Stifel Nicolaus dropped their price target on shares of Treace Medical Concepts from $9.00 to $6.00 and set a “hold” rating for the company in a research note on Friday, August 8th. UBS Group reissued a “neutral” rating and set a $6.50 price target (down from $8.60) on shares of Treace Medical Concepts in a research note on Friday, August 8th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Treace Medical Concepts in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Treace Medical Concepts has a consensus rating of “Hold” and a consensus price target of $9.67.

Institutional Investors Weigh In On Treace Medical Concepts

Several large investors have recently bought and sold shares of TMCI. Paradigm Capital Management Inc. NY bought a new stake in Treace Medical Concepts in the second quarter valued at approximately $1,577,000. Millennium Management LLC increased its stake in Treace Medical Concepts by 35.3% in the first quarter. Millennium Management LLC now owns 444,887 shares of the company’s stock valued at $3,733,000 after purchasing an additional 116,114 shares in the last quarter. Marshall Wace LLP increased its stake in Treace Medical Concepts by 256.2% in the second quarter. Marshall Wace LLP now owns 135,877 shares of the company’s stock valued at $799,000 after purchasing an additional 97,729 shares in the last quarter. AQR Capital Management LLC bought a new stake in Treace Medical Concepts in the first quarter valued at approximately $491,000. Finally, Russell Investments Group Ltd. increased its stake in Treace Medical Concepts by 133,241.9% in the second quarter. Russell Investments Group Ltd. now owns 41,336 shares of the company’s stock valued at $243,000 after purchasing an additional 41,305 shares in the last quarter. Institutional investors own 84.08% of the company’s stock.

About Treace Medical Concepts

Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.